Search results
Results from the WOW.Com Content Network
Most patients with drug-induced QT prolongation are asymptomatic and are diagnosed solely by EKG in association with a history of using medications known to cause QT prolongation. [7] A minority of patients are symptomatic and typically present with one or more signs of arrhythmia, such as lightheadedness, syncope, or palpitations. [7]
The mechanism of action of certain antiarrhythmic drugs, like amiodarone or sotalol, involve intentional pharmacological QT prolongation. In addition, high blood alcohol concentrations prolong the QT interval. [30] A possible interaction between selective serotonin reuptake inhibitors and thiazide diuretics is associated with QT prolongation. [31]
AZCERT developed the Adverse Drug Event Causality Analysis (ADECA) to evaluate drugs for their risk of causing QT prolongation and TdP. [11] As part of its ADECA reviews, AZCERT includes drugs marketed outside the United States, especially in Europe, Japan, and Canada. In addition to their use to inform healthcare decision-making, CredibleMeds ...
QT-prolonging medications such as clarithromycin, levofloxacin, or haloperidol, when taken concurrently with cytochrome P450 inhibitors, such as fluoxetine, cimetidine, or particular foods including grapefruit, can result in higher-than-normal levels of medications that prolong the QT interval in the bloodstream and therefore increase a person ...
Similarly, those taking QT prolonging medications are more likely to experience TdP if they have a genetic tendency to a prolonged QT interval, even it this tendency is concealed. [15] Arrhythmias occur more commonly in drug-induced LQTS if the medication in question has been rapidly given intravenously , or if high concentrations of the drug ...
The QT prolongation effect of ranolazine on the surface electrocardiogram is the result of inhibition of I Kr, which prolongs the ventricular action potential. [10] Ranolazine also exhibits its effects on the delayed rectifier current (hERG/ I Kr potassium channels), it readily stimulates myogenesis, it reduces a pro-oxidant inflammation ...
Lofexidine prolongs the QT interval, which can result in a severe interaction (torsade de pointes) when combined with other drugs that also prolong the QT interval. Patient-specific characteristics that increase the risk for a clinically significant drug-drug interaction include: [9] increasing age; female sex; cardiac disease
Drug interaction and deaths. [60] Sparfloxacin: 2001 US QT prolongation and phototoxicity. [2] Sulfacarbamide: 1988 Germany Dermatologic, hematologic and hepatic reactions. [3] Sulfamethoxydiazine: 1988 Germany Unknown. [3] Sulfamethoxypyridazine: 1986 UK Dermatologic and hematologic reactions. [3] Suloctidil: 1985 Germany, France, Spain ...